A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00071203" target="_blank" >RIV/00216224:14110/13:00071203 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/13:#0002114 RIV/00179906:_____/13:10191710 RIV/00023736:_____/13:00010730 RIV/00064165:_____/13:10191710

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.leukres.2013.07.021" target="_blank" >http://dx.doi.org/10.1016/j.leukres.2013.07.021</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.leukres.2013.07.021" target="_blank" >10.1016/j.leukres.2013.07.021</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes

Popis výsledku v původním jazyce

One hundred thirteen patients with myelodysplastic syndromes (MDS) with &lt;10% of bone marrow blasts received either deferiprone in a daily dose of 40-90 mg/kg (48 patients) or deferasirox in a daily dose of 10-40 mg/kg (65 patients). Median duration oftreatment was 10,9 months for deferiprone and 13,7 months for deferasirox. A substantial reduction of iron stores evaluated as a decrease in serum ferritin of more than 50% of pretreatment level was achieved in 18 patients in deferasirox group (27.7%) but not in any patient treated with deferiprone, The incidence of adverse effects (mostly gastrointestinal symptoms) was similar after administration of both the drugs. The symptoms of deferasirox toxicity were mild and mostly transient and no drug related myelosuppresive effect was observed in contrast to deferiprone where agranulocytosis occurred in 4% of patients and the treatment had to be discontinued due to side effects in 20% of patients.

Název v anglickém jazyce

A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes

Popis výsledku anglicky

One hundred thirteen patients with myelodysplastic syndromes (MDS) with &lt;10% of bone marrow blasts received either deferiprone in a daily dose of 40-90 mg/kg (48 patients) or deferasirox in a daily dose of 10-40 mg/kg (65 patients). Median duration oftreatment was 10,9 months for deferiprone and 13,7 months for deferasirox. A substantial reduction of iron stores evaluated as a decrease in serum ferritin of more than 50% of pretreatment level was achieved in 18 patients in deferasirox group (27.7%) but not in any patient treated with deferiprone, The incidence of adverse effects (mostly gastrointestinal symptoms) was similar after administration of both the drugs. The symptoms of deferasirox toxicity were mild and mostly transient and no drug related myelosuppresive effect was observed in contrast to deferiprone where agranulocytosis occurred in 4% of patients and the treatment had to be discontinued due to side effects in 20% of patients.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia Research

ISSN

0145-2126

e-ISSN

—

Svazek periodika

37

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

4

Strana od-do

1612-1615

Kód UT WoS článku

000327539700004

EID výsledku v databázi Scopus

—